Cepheid Recalls Xpert MRSA/SA Blood Culture Product Due to False Negative Results | GenomeWeb

This article, originally published July 1, has been updated from a previous version to include comments from an FDA spokesperson.

Cepheid said today that it is voluntarily recalling all lots of its Xpert MRSA/SA blood culture product, which runs on its GeneXpert PCR platform, due to false negative reports of methicillin-resistant Staphylococcus aureus.

The company said that customers can continue using the product but will need to perform confirmatory testing for any MRSA-negative/SA-positive results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions.

Ancestry.com is eyeing an expansion into genomic risk assessments, the Verge reports.